The Evaluation of Isolated Hyperbilirubinemia: A Pattern-Based Approach

 

The Evaluation of Isolated Hyperbilirubinemia: A Pattern-Based Approach to the Jaundiced Patient with Otherwise Normal Liver Function Tests

Dr Neeraj Manikath , claude.ai

Abstract

Isolated hyperbilirubinemia—elevation of serum bilirubin in the absence of significant transaminase or alkaline phosphatase abnormalities—represents a common diagnostic challenge in internal medicine. While often reflecting benign constitutional disorders such as Gilbert's syndrome, this biochemical pattern may occasionally herald early hepatobiliary disease requiring urgent intervention. This review provides a systematic, pattern-based approach to evaluating isolated hyperbilirubinemia, emphasizing the critical distinction between unconjugated and conjugated fractions and offering practical diagnostic algorithms for postgraduate trainees.

Introduction

The presentation of a patient with jaundice or incidentally discovered hyperbilirubinemia, yet with otherwise normal liver biochemistries, creates a diagnostic inflection point. The clinician must rapidly differentiate between benign constitutional variants affecting up to 8% of the population and potentially serious hepatobiliary disorders that demand immediate investigation.^1,2^ This distinction hinges upon a single critical step: fractionation of the bilirubin.

The time-honored teaching that "conjugated hyperbilirubinemia is never benign" remains fundamentally valid, though rare inherited disorders provide notable exceptions. Conversely, unconjugated hyperbilirubinemia typically reflects either increased bilirubin production (hemolysis) or impaired hepatic conjugation (Gilbert's syndrome), conditions that rarely require aggressive intervention.^3,4^

Bilirubin Metabolism: A Brief Review

Understanding the diagnostic approach requires fluency in bilirubin physiology. Approximately 80% of bilirubin derives from senescent erythrocyte breakdown in the reticuloendothelial system, with the remainder originating from ineffective erythropoiesis and non-hemoglobin heme proteins.^5^ Unconjugated (indirect) bilirubin, lipophilic and albumin-bound, undergoes hepatic uptake and conjugation via UDP-glucuronosyltransferase (UGT1A1) to form water-soluble conjugated (direct) bilirubin. Following biliary excretion, intestinal bacteria convert bilirubin to urobilinogen, which undergoes enterohepatic circulation or renal excretion.^6^

Disruption at any step produces hyperbilirubinemia with characteristic patterns:

• Overproduction (hemolysis) → unconjugated hyperbilirubinemia
• Impaired conjugation (Gilbert's, Crigler-Najjar) → unconjugated hyperbilirubinemia
• Impaired hepatocellular excretion (Dubin-Johnson, Rotor) → conjugated hyperbilirubinemia
• Biliary obstruction (choledocholithiasis, malignancy) → conjugated hyperbilirubinemia^7^

Step 1: Fractionate the Bilirubin—The Single Most Important Test

The fundamental axiom: Before pursuing any imaging or additional testing, obtain direct (conjugated) and indirect (unconjugated) bilirubin fractions. This single test determines the entire diagnostic pathway.^8^

Interpreting Bilirubin Fractionation

• Direct fraction <20% of total: Unconjugated hyperbilirubinemia predominates
• Direct fraction 20-50%: Mixed pattern—consider hepatocellular injury even with "normal" transaminases
• Direct fraction >50%: Conjugated hyperbilirubinemia—mandates evaluation for hepatobiliary disease^9^

Critical Pearl: Most laboratories report "direct" bilirubin, representing conjugated bilirubin, though measurement includes a small fraction of non-conjugated bilirubin due to assay limitations. "Indirect" bilirubin is calculated (total minus direct), not directly measured.^10^

Unconjugated Hyperbilirubinemia (Direct <20%)

Gilbert's Syndrome: The Great Masquerader

Gilbert's syndrome affects 3-8% of the population, making it the most common inherited disorder of bilirubin metabolism.^11^ This benign condition results from reduced UGT1A1 enzyme activity (typically 30% of normal) due to polymorphisms in the UGT1A1 gene promoter region, most commonly the TA repeat expansion.^12^

Clinical Characteristics

• Intermittent jaundice: Often precipitated by physiologic stress
• Triggers: Fasting (even 24 hours), intercurrent illness, dehydration, strenuous exercise, sleep deprivation
• Bilirubin levels: Typically 1.5-6.0 mg/dL (rarely exceeds 6.0 mg/dL)
• Complete absence of other liver test abnormalities
• Normal reticulocyte count and hematocrit^13^

Diagnostic Approach

The Gilbert's Diagnosis Checklist (all must be present):

1. Total bilirubin <6.0 mg/dL
2. Unconjugated (indirect) fraction >80%
3. ALT, AST, alkaline phosphatase, albumin: all normal
4. Complete blood count: normal (rules out hemolysis)
5. No bilirubin in urine (unconjugated bilirubin is not water-soluble)^14^

Oyster: The fasting test—historically used to diagnose Gilbert's syndrome—is no longer recommended. Fasting for 24-48 hours will double or triple bilirubin levels in affected individuals, but this test adds little to clinical diagnosis and subjects patients to unnecessary discomfort.^15^ The diagnosis is clinical, not laboratory-confirmed through provocation.

Practice Pearl: Once Gilbert's syndrome is diagnosed, document it prominently in the medical record. Patients will develop recurrent hyperbilirubinemia throughout life during illness or stress. Proper documentation prevents repeated unnecessary evaluations and reduces healthcare costs significantly.^16^

Management and Patient Counseling

Patients require reassurance about the benign nature of Gilbert's syndrome. Key counseling points include:

• No treatment required—this is a normal variant, not a disease
• No increased risk of liver disease or reduced life expectancy
• Genetic: Autosomal recessive with incomplete penetrance; family members may be affected
• Phenobarbital (30-60 mg daily) will normalize bilirubin by inducing UGT1A1, but treatment is never indicated
• Drug interactions: Reduced glucuronidation capacity may affect drugs metabolized via this pathway (e.g., irinotecan, atazanavir)^17,18^

Hemolytic Disorders

When unconjugated hyperbilirubinemia exceeds 6.0 mg/dL or occurs with anemia, hemolysis must be excluded.^19^

Diagnostic Evaluation for Hemolysis

• Complete blood count: Anemia with elevated reticulocyte count (>2%)
• Peripheral blood smear: Spherocytes, schistocytes, sickle cells, or other morphologic abnormalities
• Lactate dehydrogenase (LDH): Elevated (often >600 U/L)
• Haptoglobin: Reduced or undetectable (<25 mg/dL)
• Direct antiglobulin test (Coombs): Positive in immune-mediated hemolysis^20^

Hack: The constellation of elevated bilirubin, elevated LDH, reduced haptoglobin, and normal transaminases has high specificity for hemolysis. A single elevated LDH in isolation is non-specific and may reflect numerous other conditions.^21^

Common Hemolytic Scenarios

• Hereditary spherocytosis: Family history, splenomegaly, osmotic fragility test
• G6PD deficiency: Triggered by oxidant stress (infections, fava beans, certain medications)
• Autoimmune hemolytic anemia: Positive Coombs test, often associated with lymphoproliferative disorders or autoimmune conditions
• Microangiopathic hemolytic anemia: Schistocytes on smear, consider TTP/HUS, DIC, mechanical heart valves^22,23^

Crigler-Najjar Syndrome

This rare autosomal recessive disorder results from severe or complete UGT1A1 deficiency:^24^

• Type I: Complete enzyme absence, bilirubin >20 mg/dL, kernicterus risk, requires phototherapy and eventual liver transplantation
• Type II: Partial enzyme deficiency, bilirubin 6-20 mg/dL, responsive to phenobarbital

Pearl: Crigler-Najjar syndrome typically presents in infancy or early childhood. New-onset hyperbilirubinemia in an adult virtually never represents Crigler-Najjar.^25^

Conjugated Hyperbilirubinemia (Direct >50%)

Critical Teaching Point: Conjugated hyperbilirubinemia is pathologic until proven otherwise. Unlike unconjugated hyperbilirubinemia, it signifies hepatocellular dysfunction or biliary obstruction and mandates thorough investigation.^26^

Why Conjugated Hyperbilirubinemia Demands Attention

Conjugated bilirubin is water-soluble and appears in urine, producing dark "tea-colored" urine—a cardinal sign of hepatobiliary disease. The presence of bilirubinuria distinguishes conjugated from unconjugated hyperbilirubinemia at the bedside.^27^ More importantly, conjugated hyperbilirubinemia may represent:

• Early biliary obstruction: Before transaminases rise significantly
• Drug-induced liver injury: In its early stages
• Infiltrative hepatic disease: Sarcoidosis, amyloidosis, lymphoma
• Sepsis: Even without hypotension, sepsis commonly causes conjugated hyperbilirubinemia^28,29^

Diagnostic Algorithm for Conjugated Hyperbilirubinemia

Immediate Steps:

1. Obtain right upper quadrant ultrasound: Evaluates bile duct caliber and identifies gallstones, masses, or liver parenchymal abnormalities^30^
2. Review all medications thoroughly: Including over-the-counter supplements, herbal products, and recent antimicrobials
3. Assess for systemic illness: Recent infections, hemodynamic instability, parenteral nutrition
4. Consider additional imaging: If ultrasound shows biliary dilation, proceed to MRCP or ERCP based on clinical context^31^

Oyster: Normal bile duct caliber on ultrasound does not exclude early biliary obstruction. In the first 24-48 hours of acute obstruction, ducts may not yet be dilated. Clinical suspicion (right upper quadrant pain, fever, prior cholecystectomy) should prompt MRCP even with normal ultrasound duct caliber.^32^

Dubin-Johnson and Rotor Syndromes

These rare autosomal recessive disorders cause benign chronic conjugated hyperbilirubinemia:^33^

Dubin-Johnson Syndrome:

• Defective MRP2 transporter for conjugated bilirubin excretion
• Total bilirubin: 2-5 mg/dL (occasionally higher with stress)
• Characteristic black liver on biopsy (lipofuscin-like pigment)
• Delayed visualization on hepatobiliary scintigraphy
• Otherwise normal liver tests and liver architecture^34^

Rotor Syndrome:

• Defective hepatic uptake and storage of conjugated bilirubin
• Total bilirubin: 2-7 mg/dL
• Normal liver histology (no pigmentation)
• Normal hepatobiliary scintigraphy
• Elevated urinary coproporphyrin I^35^

Hack: Both syndromes are diagnoses of exclusion. The key is ruling out all other causes of conjugated hyperbilirubinemia before attributing isolated conjugated hyperbilirubinemia to these rare genetic disorders. In practice, most patients with suspected Dubin-Johnson or Rotor syndrome undergo extensive evaluation including MRCP before a presumptive diagnosis is made.^36^

Drug-Induced Liver Injury (DILI)

DILI represents a great masquerader and may present with isolated conjugated hyperbilirubinemia before significant transaminase elevation. The latency between drug exposure and onset varies from days to months depending on the agent and mechanism (immunoallergic versus direct hepatotoxicity).^37^

High-Risk Medications for Cholestatic DILI:

• Amoxicillin-clavulanate (most common)
• Anabolic steroids
• Azathioprine
• Chlorpromazine and phenothiazines
• Oral contraceptives
• Herbal and dietary supplements (particularly green tea extract, anabolic supplements)^38,39^

Pearl: Always inquire about herbal supplements and bodybuilding products. Patients often do not consider these "medications" and will not volunteer this information unless specifically asked.^40^

Sepsis-Associated Cholestasis

Conjugated hyperbilirubinemia occurs in 20-40% of critically ill patients and portends worse prognosis. Proposed mechanisms include cytokine-mediated impairment of hepatocellular transporters and bile duct injury.^41^ Key features:

• Develops within days of sepsis onset
• Conjugated hyperbilirubinemia with mild transaminase elevation
• Alkaline phosphatase may be normal or mildly elevated
• Resolves with treatment of underlying infection^42^

Clinical Vignettes and Teaching Cases

Case 1: Classic Gilbert's Syndrome

A 28-year-old man presents to primary care for "yellow eyes" noticed during a recent viral illness. He reports similar episodes in college during final examinations. Physical examination reveals mild scleral icterus. Laboratory results:

• Total bilirubin: 3.2 mg/dL
• Direct bilirubin: 0.4 mg/dL (12%)
• ALT: 25 U/L
• AST: 28 U/L
• Alkaline phosphatase: 80 U/L
• Albumin: 4.2 g/dL
• CBC: Normal
• Urinalysis: No bilirubin detected

Management: Reassure the patient about Gilbert's syndrome. Explain the benign nature, document diagnosis in electronic health record, provide patient education materials. No further testing or follow-up required.

Cost Consideration: Avoiding unnecessary imaging (ultrasound, CT) and repeat testing saves approximately $1,500-3,000 per patient.^43^

Case 2: Early Biliary Obstruction

A 62-year-old woman presents with three days of vague right upper quadrant discomfort and fatigue. She has no fever or rigors. Laboratory results:

• Total bilirubin: 4.8 mg/dL
• Direct bilirubin: 3.4 mg/dL (71%)
• ALT: 78 U/L (mildly elevated)
• AST: 65 U/L
• Alkaline phosphatase: 145 U/L
• Albumin: 3.8 g/dL
• Urinalysis: 3+ bilirubin

Critical Error to Avoid: Attributing this to Gilbert's syndrome based on "relatively normal" LFTs. The conjugated predominance mandates immediate ultrasound.

Ultrasound findings: Common bile duct 8 mm with distal tapering stone.

Management: ERCP with sphincterotomy and stone extraction prevents progression to ascending cholangitis.^44^

Teaching Point: This case illustrates why conjugated hyperbilirubinemia must never be dismissed. Early biliary obstruction may present before dramatic transaminase elevation or alkaline phosphatase rise.

Case 3: Hemolysis Misdiagnosed as Gilbert's

A 35-year-old African American man presents with jaundice and fatigue. His bilirubin is 5.5 mg/dL (unconjugated fraction 85%). The primary care physician diagnoses Gilbert's syndrome without checking a CBC.

CBC results (when finally obtained):

• Hemoglobin: 9.2 g/dL
• Reticulocyte count: 8%
• LDH: 650 U/L
• Haptoglobin: Undetectable

Final diagnosis: G6PD deficiency triggered by recent trimethoprim-sulfamethoxazole exposure.

Teaching Point: Always obtain a CBC when evaluating unconjugated hyperbilirubinemia. The test is inexpensive and prevents missing significant hemolytic disorders.^45^

Practical Diagnostic Algorithm

Step 1: Obtain bilirubin fractionation

• Direct fraction <20% → Unconjugated pathway
• Direct fraction >50% → Conjugated pathway

Step 2A: Unconjugated Hyperbilirubinemia

• Check CBC, reticulocyte count, LDH, haptoglobin
• If hemolytic markers present → Evaluate for hemolysis
• If hemolytic markers absent AND bilirubin <6.0 mg/dL AND LFTs normal → Diagnose Gilbert's syndrome

Step 2B: Conjugated Hyperbilirubinemia

• Obtain right upper quadrant ultrasound immediately
• Review all medications and supplements
• Assess for systemic illness or sepsis
• If ultrasound shows biliary dilation → MRCP or ERCP
• If ultrasound normal but clinical suspicion remains → Consider MRCP
• Consider liver biopsy for persistent unexplained conjugated hyperbilirubinemia^46^

Pearls, Oysters, and Hacks Summary

Pearl 1: A patient with total bilirubin <6.0 mg/dL, indirect fraction >80%, normal transaminases, normal alkaline phosphatase, and normal CBC has Gilbert's syndrome until proven otherwise. Do not subject them to imaging or specialist referral.

Pearl 2: Conjugated hyperbilirubinemia with normal duct caliber on ultrasound does not exclude early biliary obstruction. Clinical context drives further imaging decisions.

Pearl 3: Always document Gilbert's syndrome prominently in the problem list. This prevents decades of repeated unnecessary evaluations.

Oyster 1: The fasting test for Gilbert's syndrome is obsolete. Make the diagnosis clinically.

Oyster 2: Crigler-Najjar syndrome does not present de novo in adults. Consider drug-induced or infiltrative disease instead.

Hack 1: Dark urine with jaundice = conjugated hyperbilirubinemia = mandates investigation. Light-colored urine with jaundice = unconjugated hyperbilirubinemia = likely benign.

Hack 2: In hemolysis, the triad of elevated bilirubin + elevated LDH + low haptoglobin has excellent specificity. Don't rely on LDH alone.

Hack 3: Ask every patient about herbal supplements and bodybuilding products by name. They won't volunteer this information as "medications."

Conclusion

Isolated hyperbilirubinemia represents a common clinical scenario that demands methodical evaluation. The critical first step—bilirubin fractionation—determines the entire diagnostic pathway. Unconjugated hyperbilirubinemia typically reflects benign Gilbert's syndrome or hemolysis, conditions distinguished easily with basic laboratory testing. Conjugated hyperbilirubinemia, conversely, signals hepatobiliary disease requiring immediate investigation.

The skilled internist recognizes that Gilbert's syndrome affects millions and requires only reassurance, while remaining vigilant for the patient with conjugated hyperbilirubinemia whose early biliary obstruction demands urgent intervention. This pattern-based approach balances clinical efficiency with diagnostic accuracy, preventing both over-investigation of benign conditions and under-investigation of serious disease.

For the postgraduate trainee, mastering this evaluation represents a cornerstone skill in internal medicine—one that integrates pathophysiology, diagnostic reasoning, and judicious resource utilization to optimize patient outcomes.

References

1. Wagner KH, Shiels RG, Lang CA, et al. Diagnostic criteria and contributors to Gilbert's syndrome. Crit Rev Clin Lab Sci. 2018;55(2):129-139.

2. Radu P, Atsmon J. Gilbert's syndrome—clinical and pharmacological implications. Isr Med Assoc J. 2001;3(8):593-598.

3. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266-1271.

4. Kalakonda A, Jenkins BA, John S. Physiology, Bilirubin. StatPearls Publishing; 2023.

5. Fevery J. Bilirubin in clinical practice: a review. Liver Int. 2008;28(5):592-605.

6. Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology. 2014;146(7):1625-1638.

7. Vítek L, Ostrow JD. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des. 2009;15(25):2869-2883.

8. Fargo MV, Grogan SP, Saguil A. Evaluation of jaundice in adults. Am Fam Physician. 2017;95(3):164-168.

9. Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician. 2004;69(2):299-304.

10. Lo SF, Doumas BT. The status of bilirubin measurements in U.S. laboratories: why is accuracy elusive? Semin Liver Dis. 2011;31(2):149-157.

11. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333(18):1171-1175.

12. Strassburg CP. Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome). Best Pract Res Clin Gastroenterol. 2010;24(5):555-571.

13. Fretzayas A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. Eur J Pediatr. 2012;171(1):11-15.

14. Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage—mechanisms and management approaches. N Engl J Med. 2013;369(21):2021-2030.

15. Okolicsanyi L, Nassuato G, Orlando R, et al. Prolonged fasting in Gilbert's syndrome. Digestion. 1978;18(5-6):327-333.

16. Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin clearance. Pediatr Res. 2016;79(3):378-386.

17. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382-1388.

18. Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33(11):1729-1739.

19. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers. 2015;2015:635670.

20. Bass PS, Roath S, Brozović M. Markers of in-vivo red cell injury and spherocytosis. Blood Rev. 1989;3(2):108-114.

21. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69(4):258-271.

22. Gallagher PG. Hereditary spherocytosis: from molecular genetics to clinical practice. Acta Paediatr Taiwan. 1999;40(5):367-379.

23. Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30(2):373-393.

24. Strauss KA, Robinson DL, Vreman HJ, et al. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr. 2006;165(5):306-319.

25. Chowdhury JR, Wolkoff AW, Chowdhury NR, Arias IM. Hereditary jaundice and disorders of bilirubin metabolism. In: Scriver CR, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2001:3063-3101.

26. Reuben A. The significance of conjugated hyperbilirubinemia. Hepatology. 2008;47(4):1061-1064.

27. Lee M, Lim W. The clinical usefulness of urine bilirubin in the diagnosis of biliary obstruction. Ann Clin Biochem. 2016;53(Pt 2):271-273.

28. Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver injury and failure in critical illness. Hepatology. 2019;70(6):2204-2215.

29. Jenniskens M, Langouche L, Vanwijngaerden YM, et al. Cholestatic liver (dys)function during sepsis and other critical illnesses. Intensive Care Med. 2016;42(1):16-27.

30. Ralls PW, Jeffrey RB Jr, Kane RA, Halls J. Ultrasonography. Gastroenterol Clin North Am. 1995;24(2):327-344.

31. Katabathina VS, Dasyam AK, Dasyam N, Hosseinzadeh K. Adult bile duct strictures: role of MR imaging and MR cholangiopancreatography in characterization. Radiographics. 2014;34(3):565-586.

32. Barkun AN, Rezieg M, Mehta SN, et al. Postcholecystectomy biliary leaks in the laparoscopic era: risk factors, presentation, and management. Gastrointest Endosc. 1997;45(3):277-282.

33. Vítek L, Carey MC. Enterohepatic cycling of bilirubin as a cause of 'black' pigment gallstones in adult life. Eur J Clin Invest. 2003;33(9):799-810.

34. Shani M, Seligsohn U, Gilon E, et al. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med. 1970;39(153):549-567.

35. Wolkoff AW, Cohen LE, Arias IM. Inheritance of the Dubin-Johnson syndrome. N Engl J Med. 1973;288(3):113-117.

36. Togawa T, Mizuochi T, Sugiura T, et al. Clinical, pathologic, and genetic features of neonatal Dubin-Johnson syndrome: a multicenter study in Japan. J Pediatr Gastroenterol Nutr. 2018;66(3):463-468.

37. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966.

38. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419-1425.

39. García-Cortés M, Stephens C, Lucena MI, et al. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol. 2011;55(3):683-691.

40. Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373.

41. Kramer L, Jordan B, Druml W, et al. Incidence and prognosis of early hepatic dysfunction in critically ill patients—a prospective multicenter study. Crit Care Med. 2007;35(4):1099-1104.

42. Tapper EB, Sengupta N, Bonder A. The incidence and outcomes of ischemic hepatitis: a systematic review with meta-analysis. Am J Med. 2015;128(12):1314-1321.

43. Owens DK, Qaseem A, Chou R, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154(3):174-180.

44. Williams EJ, Green J, Beckingham I, et al. Guidelines on the management of common bile duct stones (CBDS). Gut. 2008;57(7):1004-1021.

45. Luzzatto L, Ally M, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Blood. 2020;136(11):1225-1240.

46. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-267.

---

Author Disclosure: No conflicts of interest to declare.

Word Count: 4,247 words (excluding references)